 |
|
Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
Jeong Uk Lim
Tuberc Respir Dis. 2023;86(1):14-22. Published online 2022 Oct 26 DOI: https://doi.org/10.4046/trd.2022.0081
|
|
Citations to this article as recorded by
 Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Evangelia Bogatsa, George Lazaridis, Chrysoula Stivanaki, Eleni Timotheadou
Cancers.2024; 16(9): 1619. CrossRef New targeted therapies for non-small cell lung cancer
Eun Hye Lee, Se Hyun Kwak, Chi Young Kim, Hye Ran Gwon, Eun Young Kim, Yoon Soo Chang
Journal of the Korean Medical Association.2023; 66(3): 180. CrossRef Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs
Jon Apple, Maral DerSarkissian, Anne Shah, Rose Chang, Yan Chen, Xuanhao He, Justin Chun
Journal of Comparative Effectiveness Research.2023;[Epub] CrossRef Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
Jae Kyeom Sim, Juwhan Choi, Sung Yong Lee
The Korean Journal of Internal Medicine.2023; 38(6): 787. CrossRef Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection
Hwa Park, Yoo Choi, Ju-Sik Yun, Sang-Yun Song, Kook-Joo Na, Joon Yoon, Chang-Seok Yoon, Hyung-Joo Oh, Young-Chul Kim, In-Jae Oh
Cancers.2023; 15(23): 5679. CrossRef
|